Role of moxifloxacin in the treatment of community-acquired pneumonia
Abstract
INTRODUCTION: Community-acquired pneumonia is a common cause of morbidity and mortality throughout the world. Moxifloxacin, a new generation fluoroquinolone have become an attractive therapeutic alternative in the treatment of community-acquired pneumonia because of its excellent pharmacokinetic parameters and wide antimicrobial spectrum. AIMS: The authors reviewed the role of moxifloxacin in the treatment of community-acquired pneumonia based on their experience and the data of the literature. METHODS: The authors studied the clinical outcome of the patients treated with moxifloxacin due to community-acquired pneumonia in their hospital ward between May 1, 2002 and May 1, 2003. RESULTS: Four patients with pneumonia were treated ineffectively by moxifloxacin during a year. Serious clinical and radiological progression occurred to each patient despite moxifloxacin therapy, and two patients had to be admitted to intensive care unit. Three patients were successfully treated by 2nd or 3rd generation cephalosporin and clarithromycin, but one patient died. CONCLUSIONS: The authors call attention with these cases to the fact that in clinical trials oral moxifloxacin therapy was not more efficient either clinically or microbiologically than standard therapy in the treatment of community-acquired pneumonia. Moxifloxacin therapy is recommended to be reserved to patients allergic or not responsive to other antibiotics, and in the case of infections due to penicillin-resistant…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.